
Need information ?
Contact us
You are here
VIDAS® HIV panel
Advanced 4th generation assays for earlier diagnosis
The VIDAS® HIV panel provides a combination of advanced 4th generation assays for improved detection of acute HIV during the critical “window period”.
- Combined detection of anti-HIV-1 (groups M and O) and anti-HIV-2 total immunoglobulins + HIV-1 p24 antigen
- True dual information: differentiation of Ag and Ab signals
- Highest p24 Ag sensitivity currently available
- Easy-to-use solution
Do you need more information
Many of the 35.3 million people infected with HIV worldwide are unaware of their condition, as symptoms may be absent or non-specific. In addition, there is a mean period of 3 weeks between contamination and the appearance of the first anti-HIV serum antibodies1. Early detection of seroconversions is thus one of the main HIV diagnostic challenges.
The VIDAS® automated HIV infection screening tests allow simultaneous detection of p24 antigen and anti-HIV antibodies enabling the time lapse between contamination and diagnosis of the infection to be decreased. Identifying more primary infections can make a key difference in reducing transmission. Providing appropriate therapy as fast as possible is also essential to improve patient outcome.
A unique assay concept
The VIDAS® HIV panel:
vidas-hiv-panel_2.png

Assay concept:
Click to enlarge »
Excellent performances
- Best analytical sensitivity compared to other commonly-used assays2,3
- Lowest limit of detection of HIV infection2,3
- Highest p24 Ag sensitivity currently available (Lower Limit of Detection against the WHO standard):
- VIDAS® HIV Duo Ultra: 0.66 IU/mL3
- VIDAS® HIV Duo Quick: 0.43 IU/mL3
- VIDAS® HIV P24:0.73 - 1.15 IU/mL3
Ease of use and flexibility for your lab
- Easy-to-use solution
- One patient, one strip
- Renowned VIDAS® robustness and reliability
References:
- Kleinman S., et al. Transfusion Medicine Reviews. July 1997. Vol. 11, N° 3 p. 155-172.
- Ly TD, et al. 2007 Jul; 143(1):86-94. Epub 2007 Mar 28.
- Miedouge M, et al. J Clin Virol. 2011 Jan;50(1):57-60. doi: 10.1016/j.jcv.2010.09.003.
VIDAS® HIV DUO Ultra |
VIDAS® HIV DUO Quick |
VIDAS® P24 II | |
---|---|---|---|
Reference | 30443 | 30447 | 30117 |
Tests / kit | 60 | 60 | 30 |
Sample type | Serum or plasma on lithium heparinate or EDTA | ||
Sample volume | 200 µL | ||
Calibration & control stability | 14 days | ||
Results | Separated results for Ag and Ab |
Global results | |
Sensitivity in Ag | 11.5 pg/ml HIV Ag | 16.5 pg/ml HIV Ag | 11.25 pg/ml HIV Ag |
VIDAS® HIV P24 II Confirmation | |
---|---|
Reference | 30 444 |
Tests / kit | 60 tests |
Find more technical details on www.myvidas.com.
Consult your local bioMérieux representative for product availability in your country.
Related Publications
- Ly TD, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods. 2007 Jul;143(1):86-94. Epub 2007 Mar 28.
- Miedouge M, Grèze M, Bailly A, Izopet J. Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard. J Clin Virol. 2011 Jan;50(1):57-60. doi: 10.1016/j.jcv.2010.09.003.
Guidelines
- World Health Organization
- Guidance on provider-initiated HIV testing and counselling in health facilities
- Delivering HIV test results and messages for re-testing and counselling in adults
Find more scientific and educational resources on www.myvidas.com.
- Clinical Diagnostics
- Industrial Microbiology
- News & Events
- Resources
- About us
- Contact Info
- My selection
bioMérieux Sweden AB - Hantverksvägen 15 - SE-436 33 Askim, SWEDEN
- Legal Notice
- Privacy
- Cookie Policy
- Sitemap
- Contact
- Copyright 2022 bioMérieux SA